Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE

  • Irene Virgolini
  • Valentina Ambrosini
  • Jamshed B. Bomanji
  • Richard P. Baum
  • Stefano Fanti
  • Michael Gabriel
  • Nikolaos D. Papathanasiou
  • Giovanna Pepe
  • Wim Oyen
  • Clemens De Cristoforo
  • Arturo ChitiEmail author


The aim of these guidelines is to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin (SST) receptor PET/CT imaging using 68Ga-DOTA-conjugated peptides, analogues of octreotide, that bind to SST receptors. This imaging modality should not be regarded as the only approach to visualizing tumours expressing SST receptors or as excluding other imaging modalities useful for obtaining comparable results. The corresponding guidelines of 111In-pentetreotide scintigraphy imaging have been considered and partially integrated with this text. The same has been done with the relevant and recent literature in this field and the final result has been discussed by distinguished experts.


PET Tumour imaging Procedure guidelines Peptides Neuroendocrine tumours Indications 



The EANM has written and approved guidelines to promote the use of high-quality nuclear medicine procedures. These general recommendations cannot be applied to all patients in all practice settings. The guidelines should not be deemed inclusive of all proper procedures and exclusive of other procedures reasonably directed to obtaining the same results. The spectrum of patients seen in a specialized practice setting may be different than the spectrum usually seen in a more general setting. The appropriateness of a procedure will depend in part on the prevalence of disease in the patient population. In addition, resources available for patient care may vary greatly from one European country or one medical facility to another. For these reasons, the guidelines cannot be rigidly applied.


  1. 1.
    Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 2001;42(7):1134–8.PubMedGoogle Scholar
  2. 2.
    Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. (111)In-Pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37(7):1441–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology. 2009;90(2):184–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34(7):982–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24(4):389–427.CrossRefPubMedGoogle Scholar
  6. 6.
    Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30(5):781–93.CrossRefPubMedGoogle Scholar
  7. 7.
    Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol. 2001;12 Suppl 2:S51–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med 1995;25(3):251–61.CrossRefPubMedGoogle Scholar
  9. 9.
    Briganti V, Sestini R, Orlando C, et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res 1997;3:2385–91.PubMedGoogle Scholar
  10. 10.
    Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med 2000;44(1):42–9.PubMedGoogle Scholar
  11. 11.
    Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998;25(10):1396–403.CrossRefPubMedGoogle Scholar
  12. 12.
    Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716–31.CrossRefPubMedGoogle Scholar
  13. 13.
    Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med 1998;25:639–58.CrossRefPubMedGoogle Scholar
  14. 14.
    Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111 pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 1995;36:542–49.PubMedGoogle Scholar
  15. 15.
    Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38(6):853–8.PubMedGoogle Scholar
  16. 16.
    Kowalski J, Henze M, Schuhmacher J, Maecke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D-Phe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34(10):1617–26.CrossRefPubMedGoogle Scholar
  18. 18.
    Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28(12):1751–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30(10):1338–47.CrossRefPubMedGoogle Scholar
  20. 20.
    Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51(5):669–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AM, Santini D, et al. Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51(3):353–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48(4):508–18.CrossRefPubMedGoogle Scholar
  23. 23.
    Ambrosini V, Marzola MC, Rubello D, Fanti S. (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37(1):46–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37(1):49–57.CrossRefPubMedGoogle Scholar
  25. 25.
    Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112(11):2447–55.CrossRefPubMedGoogle Scholar
  26. 26.
    Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35(8):1431–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother 2008;62(10):667–71.CrossRefPubMedGoogle Scholar
  28. 28.
    Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50(12):1927–32.CrossRefPubMedGoogle Scholar
  29. 29.
    Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009;30(4):281–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Klutmann S, Bohuslavizki KH, Brenner W, Behnke A, Tietje N, Kröger S, et al. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med 1998;39(11):1913–7.PubMedGoogle Scholar
  31. 31.
    Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005;46(5):763–9.PubMedGoogle Scholar
  32. 32.
    Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 2010;37(1):67–77.CrossRefPubMedGoogle Scholar
  33. 33.
    Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50(8):1214–21.CrossRefPubMedGoogle Scholar
  34. 34.
    Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010;37(4):722–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, et al. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 2002;29:147–57.CrossRefPubMedGoogle Scholar
  36. 36.
    Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009;50:1427–34.CrossRefPubMedGoogle Scholar
  37. 37.
    EANM Radiopharmacy Committee. Guidelines on current good radiopharmacy practice (cGRPP) in the preparation of radiopharmaceuticals. European Association of Nuclear Medicine; 2007. Accessed 24 June 2010.
  38. 38.
    Elsinga P, Todde S, Penuelas I, Meyer G, Farstad B, Faivre-Chauvet A, et al; Radiopharmacy Committee of the EANM. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2010;37:1049–62.CrossRefPubMedGoogle Scholar
  39. 39.
    Velikyan I, Beyer GJ, Långström B. Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem 2004;15:554–60.CrossRefPubMedGoogle Scholar
  40. 40.
    Meyer GJ, Maecke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004;31:1097–104.CrossRefPubMedGoogle Scholar
  41. 41.
    Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48:1741–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Di Pierro D, Rizzello A, Cicoria G, Lodi F, Marengo M, Pancaldi D, et al. Radiolabelling, quality control and radiochemical purity assessment of the octreotide analogue 68Ga DOTA NOC. Appl Radiat Isot 2008;66:1091–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478–85.CrossRefPubMedGoogle Scholar
  44. 44.
    Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun 2007;28:870–5.CrossRefPubMedGoogle Scholar
  45. 45.
    Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:72–9.CrossRefPubMedGoogle Scholar

Copyright information

© EANM 2010

Authors and Affiliations

  • Irene Virgolini
    • 1
  • Valentina Ambrosini
    • 2
  • Jamshed B. Bomanji
    • 3
  • Richard P. Baum
    • 4
  • Stefano Fanti
    • 2
  • Michael Gabriel
    • 1
  • Nikolaos D. Papathanasiou
    • 3
  • Giovanna Pepe
    • 5
  • Wim Oyen
    • 6
  • Clemens De Cristoforo
    • 1
  • Arturo Chiti
    • 5
    Email author
  1. 1.Medical University of InnsbruckInnsbruckAustria
  2. 2.Nuclear MedicineS. Orsola-Malpighi HospitalBolognaItaly
  3. 3.Institute of Nuclear MedicineUniversity College HospitalLondonUK
  4. 4.Zentralklinik Bad BerkaBad BerkaGermany
  5. 5.Istituto Clinico HumanitasRozzano (MI)Italy
  6. 6.University Medical Center NijmegenNijmegenThe Netherlands

Personalised recommendations